Atria Investments Inc Buys 3,418 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Atria Investments Inc lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 47.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,628 shares of the biopharmaceutical company’s stock after buying an additional 3,418 shares during the quarter. Atria Investments Inc’s holdings in Agios Pharmaceuticals were worth $472,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Harbor Capital Advisors Inc. increased its stake in Agios Pharmaceuticals by 19.3% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 39,090 shares of the biopharmaceutical company’s stock worth $1,737,000 after buying an additional 6,320 shares in the last quarter. Oak Ridge Investments LLC raised its stake in Agios Pharmaceuticals by 14.6% during the 3rd quarter. Oak Ridge Investments LLC now owns 40,378 shares of the biopharmaceutical company’s stock valued at $1,794,000 after purchasing an additional 5,142 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Agios Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,942 shares of the biopharmaceutical company’s stock valued at $486,000 after purchasing an additional 4,272 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 363 shares in the last quarter. Finally, Creative Planning boosted its stake in Agios Pharmaceuticals by 35.8% in the 3rd quarter. Creative Planning now owns 15,640 shares of the biopharmaceutical company’s stock worth $695,000 after purchasing an additional 4,120 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Leerink Partnrs lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Raymond James reiterated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a research note on Friday, November 1st. Finally, Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $52.33.

Insider Activity

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Trading Up 0.4 %

AGIO opened at $54.62 on Thursday. Agios Pharmaceuticals, Inc. has a 12-month low of $20.96 and a 12-month high of $62.58. The business’s fifty day simple moving average is $47.03 and its 200-day simple moving average is $44.28. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of 4.81 and a beta of 0.75.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.